Cited by 64Atrial Fibrillation Management and OutcomesAcute Ischemic Stroke ManagementVenous Thromboembolism Diagnosis and Management

Residual Risk of Stroke and Death in Anticoagulated Patients According to the Type of Atrial Fibrillation: AMADEUS Trial

Open access
Senoo, Keitaro, Lip, Gregory Y.H., Lane, Deirdre A., Büller, Harry R., Kotecha, Dipak·2015·Stroke

Abstract

BACKGROUND AND PURPOSE: Atrial fibrillation (AF) and heart failure frequently coexist and are associated with increased morbidity and mortality. We investigated the prognosis of anticoagulated patients with permanent AF and nonpermanent AF according to preexisting heart failure in the AMADEUS (Evaluating the Use of SR34006 Compared to Warfarin or Acenocoumarol in Patients With Atrial Fibrillation) trial. METHODS: The primary outcome was a composite of cardiovascular death and stroke or systemic embolism, analyzed using a Cox proportional hazards model, adjusted for baseline age, sex, diabetes mellitus, hypertension, creatinine, and previous cardiovascular diseases. The median follow-up was 11.6 months (interquartile range, 6.2-15.2). RESULTS: Nonpermanent AF was present in 2072 patients (46% of cohort), of which 339 (16%) had preexisting heart failure. A total of 2484 patients had permanent AF (54% of cohort), with a higher burden of heart failure including 730 patients (29%; P<0.001). Overall, death because of cardiovascular causes occurred in 57 patients and 45 had stroke or systemic embolism (1.4/100 person-years for each). Overall, the adjusted incidence of the composite outcome was higher in patients with permanent AF than in patients with nonpermanent AF. In multivariate analysis, permanency of AF, creatinine, prior cerebrovascular events, and previous coronary disease were independently associated with the primary outcome. The hazard ratio for permanent versus nonpermanent AF was 1.68 (95% confidence interval, 1.08-2.55; P=0.02). The presence of heart failure increased the risk of adverse outcomes in a similar way in both permanent and nonpermanent AF (interaction P value=0.76). CONCLUSIONS: The risk of cardiovascular death, stroke, or systemic embolism is higher in anticoagulated patients with permanent AF than in those with nonpermanent AF, regardless of preexisting heart failure.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1161/strokeaha.115.009487

Cites

32 of 32 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Research works printed but not linked: 4

  1. Aboaf AP, Wolf PS. Paroxysmal atrial fibrillation. A common but neglected entity. Arch Intern Med. 1996;156:362-367
  2. Petersen P, Godtfredsen J. Embolic complications in paroxysmal atrial fibrillation. Stroke. 1986;17:622-626
  3. Dries DL, Exner DV, Gersh BJ, Domanski MJ, Waclawiw MA, Stevenson LW. Atrial fibrillation is associated with an increased risk for mortality and heart failure progression in patients with asymptomatic and symptomatic left ventricular systolic dysfunction: a retrospective analysis of the SOLVD trials. Studies of Left Ventricular Dysfunction. J Am Coll Cardiol. 1998;32:695-703
  4. Lip GY, Nieuwlaat R, Pisters R, Lane DA, Crijns HJ. Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the euro heart survey on atrial fibrillation. Chest. 2010;137:263-272

Cited by

Sorted by citations

Authors
Senoo, K., Lip, G. Y. H., Lane, D. A., Büller, H. R., & Kotecha, D.
Affiliations
  • Birmingham City Hospital (GB)
  • From the University of Birmingham Centre for Cardiovascular Sciences, Cardiovascular Department, City Hospital, Birmingham, United Kingdom (K.S., G.Y.H.L., D.A.L., D.K.); Aalborg Thrombosis Research Unit, Department of Clinical Medicine, Aalborg University, Aalborg, Denmark (G.Y.H.L.); and Department of Vascular Medicine, Academic Medical Centre, Amsterdam, The Netherlands (H.R.B.).
Venue
Stroke
Published
2015-09
Volume
46
Issue
9
Pages
2523-2528
ISSN
  • 0039-2499 (ISSN-L)
  • 1524-4628
OpenAlex
W2152235423
Cited by
64
References
32
Citations by year
2026: 2 · 2025: 2 · 2024: 4 · 2023: 2 · 2022: 6 · 2021: 8 · 2020: 5 · 2019: 9 · 2018: 7 · 2017: 7 · 2016: 10 · 2015: 2
FWCI
6.29
Type
journal article
Language
en
Open access
Locations
  • Stroke (publishedVersion)
  • PubMed (publishedVersion)
  • Pure Amsterdam UMC (publishedVersion, other-oa)
  • Data Archiving and Networked Services (DANS) (submittedVersion)
  • University of Birmingham Research Portal (University of Birmingham) (submittedVersion, other-oa)
  • VBN Forskningsportal (Aalborg Universitet) (submittedVersion)
Funders
  • Sanofi
  • National Institute for Health and Care Research (CL-2012-09-001)
Topics
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Atrial Fibrillation Management and Outcomes
  • Health Sciences › Medicine › Epidemiology › Acute Ischemic Stroke Management
  • Health Sciences › Medicine › Internal Medicine › Venous Thromboembolism Diagnosis and Management
Keywords
atrial fibrillation, permanent atrial fibrillation, heart failure, anticoagulation, cardiovascular mortality, systemic embolism, warfarin, acenocoumarol, prognosis, creatinine, cerebrovascular events, coronary disease
MeSH terms
Aged, Aged, 80 and over, Anticoagulants, Atrial Fibrillation, Chronic Disease, Embolism, Female, Follow-Up Studies, Heart Failure, Humans, Male, Middle Aged, Prognosis, Risk, Multicenter Studies as Topic, Comorbidity, Randomized Controlled Trials as Topic, Stroke

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review